Online inquiry

IVTScrip™ mRNA-Human ARRDC1-AS1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK23278MR)

This product GTTS-WK23278MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ARRDC1-AS1 protein. This product can be used in Ciliated epithelial cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 85026
UniProt ID Q9H2J1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ARRDC1-AS1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK23278MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK5348MR IVTScrip™ mRNA-Human CD71, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD71
GTTS-WK26242MR IVTScrip™ mRNA-Human ARL4C, (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARL4C
GTTS-WK5121MR IVTScrip™ mRNA-Human Go-alpha, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Go-alpha
GTTS-WK23861MR IVTScrip™ mRNA-Human ARNT, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARNT
GTTS-WK15154MR IVTScrip™ mRNA-Human AMN1, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMN1
GTTS-WK19108MR IVTScrip™ mRNA-Human ANKRD20A4, (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ANKRD20A4
GTTS-WK11259MR IVTScrip™ mRNA-Human ACTG1, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACTG1
GTTS-WK28580MR IVTScrip™ mRNA-Human ARHGAP1, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARHGAP1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW